Inhibition of HIV replication: A powerful antiviral strategy by IFN-β gene delivery in CD4+ cells

Biochemical Pharmacology

Volumn 74, Issue 6, 2007, Pages 898-910

  Brule, Fabienne ^a   Khatissian, Emmanuel ^a   Benani, Alexandre ^d   Bodeux, Audrey ^a   Montagnier, Luc ^c   Piette, Jacques ^a   Lauret, Evelyne ^b   Ravet, Emmanuel ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b INSERM   (France)

^c Prevention UNESCO   (France)

^d Institut National de la Sant é et de la Recherche Medicale   (France)

Author keywords

Gene therapy; HIV; IFN ; Lentiviral vector

Indexed keywords

ADENYLATE KINASE; APOLIPOPROTEIN D; ASPARTATE AMMONIA LIGASE; BETA INTERFERON; CCAAT ENHANCER BINDING PROTEIN BETA; CD24 ANTIGEN; CD31 ANTIGEN; CHIMERIN; COLLAGEN TYPE 4; CYCLIN A1; CYSTATHIONINE BETA SYNTHASE; DIPEPTIDYL PEPTIDASE IV; GUANINE NUCLEOTIDE BINDING PROTEIN; HEPARAN SULFATE; HERMES ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 16; INTERLEUKIN 8; LENTIVIRUS VECTOR; PROTEIN P73; S6 KINASE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INFLAMMATION; METABOLISM; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICS; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; GENE THERAPY; GENETIC VECTORS; HAPLORHINI; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; INTERFERON-BETA; MICE; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 34547811393     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.06.036     Document Type: Article

References (66)

1. Shafer R.W., and Vuitton D.A. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother 53 2 (1999) 73-86
2. Turner B.J. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis 185 Suppl. 2 (2002) S143-S151
3. Nunez M., and Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 28 1 (2005) 53-66
4. Nolan D., Reiss P., and Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 4 2 (2005) 201-218
5. + T cells. Nat Med 9 6 (2003) 727-728
6. Tang J.W., and Pillay D. Transmission of HIV-1 drug resistance. J Clin Virol 30 1 (2004) 1-10
7. Pillay D., Taylor S., and Richman D.D. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol 10 4 (2000) 231-253
8. Hurez V., Hautton R.D., Oliver J., Matthews R.J., and Weaver C.K. Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction. Immunol Res 26 1-3 (2002) 131-141
9. Humeau L.M., Binder G.K., Lu X., Slepushkin V., Merling R., Echeagaray P., et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 9 6 (2004) 902-913
10. Amsellem S., Ravet E., Fichelson S., Pflumio F., and Dubart-Kupperschmitt A. Maximal lentivirus-mediated gene transfer and sustained transgene expression in human hematopoietic primitive cells and their progeny. Mol Ther 6 5 (2002) 673-677
11. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 3 (2003) 255-256
12. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 5644 (2003) 415-419
13. Woods N.B., Muessig A., Schmidt M., Flygare J., Olsson K., Salmon P., et al. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101 4 (2003) 1284-1289
14. Themis M., Waddington S.N., Schmidt M., von Kalle C., Wang Y., Al-Allaf F., et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12 4 (2005) 763-771
15. Chen J.D., Bai X., Yang A.G., Cong Y., and Chen S.Y. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med 3 10 (1997) 1110-1116
16. Chinen J., Aguilar-Cordova E., Ng-Tang D., Lewis D.E., and Belmont J.W. Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene. Hum Gene Ther 8 7 (1997) 861-868
17. Chang H.K., Gendelman R., Lisziewicz J., Gallo R.C., and Ensoli B. Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther 1 3 (1994) 208-216
18. Chaloin L., Lehmann M.J., Sczakiel G., and Restle T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res 30 18 (2002) 4001-4008
19. Browning C.M., Cagnon L., Good P.D., Rossi J., Engelke D.R., and Markovitz D.M. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J Virol 73 6 (1999) 5191-5195
20. Bai J., Gorantla S., Banda N., Cagnon L., Rossi J., and Akkina R. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 1 3 (2000) 244-254
21. Kim J.H., McLinden R.J., Mosca J.D., Vahey M.T., Greene W.C., and Redfield R.R. Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors. J Acquir Immune Defic Syndr Hum Retrovirol 12 4 (1996) 343-351
22. Strayer D.S., Akkina R., Bunnell B.A., Dropulic B., Planelles V., Pomerantz R.J., et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 11 6 (2005) 823-842
23. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K., et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 8 7 (2002) 681-686
24. Qin X.F., An D.S., Chen I.S., and Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100 1 (2003) 183-188
25. Vieillard V., Lauret E., Rousseau V., and De Maeyer E. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta. Proc Natl Acad Sci USA 91 7 (1994) 2689-2693
26. Kornbluth R.S., Oh P.S., Munis J.R., Cleveland P.H., and Richman D.D. The role of interferons in the control of HIV replication in macrophages. Clin Immunol Immunopathol 54 2 (1990) 200-219
27. Hansen B.D., Nara P.L., Maheshwari R.K., Sidhu G.S., Bernbaum J.G., Hoekzema D., et al. Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol 66 12 (1992) 7543-7548
28. Poli G., Orenstein J.M., Kinter A., Folks T.M., and Fauci A.S. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244 4904 (1989) 575-577
29. Coccia E.M., Krust B., and Hovanessian A.G. Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem 269 37 (1994) 23087-23094
30. Baca-Regen L., Heinzinger N., Stevenson M., and Gendelman H.E. Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J Virol 68 11 (1994) 7559-7565
31. Shirazi Y., and Pitha P.M. Interferon alpha-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells. Virology 193 1 (1993) 303-312
32. Vieillard V., Cremer I., Lauret E., Rozenbaum W., Debre P., Autran B., et al. Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens. Proc Natl Acad Sci USA 94 21 (1997) 11595-11600
33. Hadida F., De Maeyer E., Cremer I., Autran B., Baggiolini M., Debre P., et al. Acquired constitutive expression of interferon beta after gene transduction enhances human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity by a RANTES-dependent mechanism. Hum Gene Ther 10 11 (1999) 1803-1810
34. Vieillard V., Jouveshomme S., Leflour N., Jean-Pierre E., Debre P., De Maeyer E., et al. Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection. J Virol 73 12 (1999) 10281-10288
35. Gay W., Lauret E., Boson B., Larghero J., Matheux F., Peyramaure S., et al. Low autocrine interferon beta production as a gene therapy approach for AIDS: infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251. Retrovirology 1 1 (2004) 29
36. Sirven A., Pflumio F., Zennou V., Titeux M., Vainchenker W., Coulombel L., et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96 13 (2000) 4103-4110
37. Matheux F., Le Grand R., Rousseau V., De Maeyer E., Dormont D., and Lauret E. Macaque lymphocytes transduced by a constitutively expressed interferon beta gene display an enhanced resistance to SIVmac251 infection. Hum Gene Ther 10 3 (1999) 429-440
38. Yam P.Y., Yee J.K., Ito J.I., Sniecinski I., Doroshow J.H., Forman S.J., et al. Comparison of amphotropic and pseudotyped VSV-G retroviral transduction in human CD34+ peripheral blood progenitor cells from adult donors with HIV-1 infection or cancer. Exp Hematol 26 10 (1998) 962-968
39. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72 12 (1998) 9873-9880
40. Salter R.D., Howell D.N., and Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21 3 (1985) 235-246
41. Ravet E., Reynaud D., Titeux M., Izac B., Fichelson S., Romeo P.H., et al. Characterization of DNA-binding-dependent and -independent functions of SCL/TAL1 during human erythropoiesis. Blood 103 9 (2004) 3326-3335
42. Geleziunas R., Bour S., and Wainberg M.A. Cell surface down-modulation of CD4 after infection by HIV-1. FASEB J 8 9 (1994) 593-600
43. Belbin T.J., Singh B., Barber I., Socci N., Wenig B., Smith R., et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62 4 (2002) 1184-1190
44. Iolascon A., Volinia S., Borriello A., Giordani L., Moretti A., Servedio V., et al. Genes transcriptionally modulated by interferon alpha2a correlate with the cytokine activity. Haematologica 89 9 (2004) 1046-1053
45. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61 5 (2001) 2129-2137
46. Guan E., Wang J., and Norcross M.A. Amino-terminal processing of MIP-1beta/CCL4 by CD26/dipeptidyl-peptidase IV. J Cell Biochem 92 1 (2004) 53-64
47. Berenson R.J., Andrews R.G., Bensinger W.I., Kalamasz D., Knitter G., Buckner C.D., et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 81 3 (1988) 951-955
48. Scacheri P.C., Rozenblatt-Rosen O., Caplen N.J., Wolfsberg T.G., Umayam L., Lee J.C., et al. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 101 7 (2004) 1892-1897
49. Fish R.J., and Kruithof E.K. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors. BMC Mol Biol 5 (2004) 9
50. Auty A., and Saleh A. Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. Can J Neurol Sci 32 3 (2005) 366-368
51. Mirani M., Elenkov I., Volpi S., Hiroi N., Chrousos G.P., and Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 169 11 (2002) 6361-6368
52. Valenzuela A., Blanco J., Callebaut C., Jacotot E., Lluis C., Hovanessian A.G., et al. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol 158 8 (1997) 3721-3729
53. Amella C.A., Sherry B., Shepp D.H., and Schmidtmayerova H. Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP. J Virol 79 9 (2005) 5625-5631
54. Richardson R.M., Tokunaga K., Marjoram R., Sata T., and Snyderman R. Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity. Role of signal strength and receptor desensitisation. J Biol Chem 278 18 (2003) 15867-15873
55. Andreakos E., Williams R.O., Wales J., Foxwell B.M., and Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 103 39 (2006) 14459-14464
56. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72 9 (2006) 1161-1179
57. Cai Y., Liu Y., Yu D., and Zhang X. Down-regulation of transcription of the proapoptotic gene BNip3 in cultured astrocytes by murine coronavirus infection. Virology 316 1 (2003) 104-115
58. Das A.T., Brummelkamp T.R., Westerhout E.M., Vink M., Madiredjo M., Bernards R., et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 78 5 (2004) 2601-2605
59. Boden D., Pusch O., Lee F., Tucker L., and Ramratnam B. Human immunodeficiency virus type 1 escape from RNA interference. J Virol 77 21 (2003) 11531-11535
60. Wilderman M.J., Sun J., Jassar A.S., Kapoor V., Khan M., Vachani A., et al. Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 65 18 (2005) 8379-8387
61. Yoshida J., Mizuno M., Fujii M., Kajita Y., Nakahara N., Hatano M., et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15 1 (2004) 77-86
62. Tada H., Maron D.J., Choi E.A., Barsoum J., Lei H., Xie Q., et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 108 1 (2001) 83-95
63. Streck C.J., Dickson P.V., Ng C.Y., Zhou J., Hall M.M., Gray J.T., et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther 13 1 (2006) 99-106
64. Triantaphyllopoulos K., Croxford J., Baker D., and Chernajovsky Y. Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther 5 2 (1998) 253-263
65. Sharief M.K., Semra Y.K., Seidi O.A., and Zoukos Y. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 120 1/2 (2001) 199-207
66. Gardner M.B. Simian AIDS: an historical perspective. J Med Primatol 32 4/5 (2003) 180-186